NASDAQ:CHMA - Chiasma Stock Price, Forecast & News

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

Chiasma Inc (NASDAQ:CHMA) posted its earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.01. View Chiasma's Earnings History.

Chiasma is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Chiasma.

6 brokers have issued 1-year price targets for Chiasma's shares. Their forecasts range from $11.00 to $18.00. On average, they expect Chiasma's stock price to reach $13.80 in the next year. This suggests a possible upside of 198.1% from the stock's current price. View Analyst Price Targets for Chiasma.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chiasma.

Media stories about CHMA stock have been trending extremely negative on Monday, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Chiasma earned a news impact score of -4.5 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Chiasma.

Chiasma saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,780,000 shares, an increase of 11.9% from the December 31st total of 1,590,000 shares. Based on an average daily trading volume, of 266,800 shares, the short-interest ratio is currently 6.7 days. Currently, 5.8% of the company's shares are sold short. View Chiasma's Current Options Chain.

Some companies that are related to Chiasma include Eagle Pharmaceuticals (EGRX), Provention Bio (PRVB), CannTrust (CNTTF), Cytokinetics (CYTK), ANI Pharmaceuticals (ANIP), ImmunoGen (IMGN), Homology Medicines (FIXX), Retrophin (RTRX), Basilea Pharmaceutica (BPMUF), Collegium Pharmaceutical (COLL), Akero Therapeutics (AKRO), Emisphere Technologies (EMIS), TherapeuticsMD (TXMD), Flexion Therapeutics (FLXN) and Frequency Therapeutics (FREQ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals PLC- (GWPH), BioDelivery Sciences International (BDSI), Alnylam Pharmaceuticals (ALNY), Progenics Pharmaceuticals (PGNX), Viking Therapeutics (VKTX), Walgreens Boots Alliance (WBA), Exelixis (EXEL) and Inovio Pharmaceuticals (INO).

(CHMA) raised $76 million in an initial public offering on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CHMA stock can currently be purchased for approximately $4.63.

Chiasma has a market capitalization of $194.55 million. The biotechnology company earns $-31,260,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis. Chiasma employs 18 workers across the globe.View Additional Information About Chiasma.

The official website for Chiasma is http://www.chiasmapharma.com/.

Chiasma's mailing address is 460 Totten Pond Road Suite 530, Waltham MA, 02451. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]